Advanced search

Vol 55, No 3 (2017)
Review paper
Published online: 2017-09-29

open access

View PDF Download PDF file
Page views 2143
Article views/downloads 2115
Get Citation

Connect on Social Media

Connect on Social Media

Circulating tumor cells in urological cancers

Martin Cegan1, Christopher Kobierzycki2, Katarina Kolostova3, Imrich Kiss3, Vladimir Bobek324, Robert Grill5
DOI: 10.5603/FHC.a2017.0015
Pubmed: 28994093
Folia Histochem Cytobiol 2017;55(3):107-113.

Abstract

Circulating tumor cells (CTC) represent a very small subpopulation of the cancer cells found in the bloodstream of patients in the metastatic phase of neoplastic disease. Due to the timeline of the disease, they are regarded as a negative prognostic marker. This study focused on determining CTC percentages; these values vary be­tween different types of cancer. In addition to their diagnostic use, CTCs may also be used to treat the disease. Calculating CTC population size and analyzing their biology in patients in advanced stages of cancer may prove valuable in creating a molecular profile for the disease. This would strongly encourage diagnostics and enable personalized treatment. We here present an analysis of recent data on CTCs in urological cancers and their potential uses.

Keywords: CTCscirculating tumor cellsprostate cancerkidney cancerbladder cancercultivationin vitrogene expression

Article available in PDF format

View PDF Download PDF file

References

  1. Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004; 10(20): 6897–6904.
    CrossRefPubMed
  2. Tanaka F, Yoneda K, Kondo N, et al. Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res. 2009; 15(22): 6980–6986.
    CrossRefPubMed
  3. Hofman V, Bonnetaud C, Ilie MI, et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin Cancer Res. 2011; 17(4): 827–835.
    CrossRefPubMed
  4. Liberko M, Kolostova K, Bobek V. Essentials of circulating tumor cells for clinical research and practice. Crit Rev Oncol Hematol. 2013; 88(2): 338–356.
    CrossRefPubMed
  5. Yu M, Stott S, Toner M, et al. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol. 2011; 192(3): 373–382.
    CrossRefPubMed
  6. Turajlic S, Swanton C. Metastasis as an evolutionary process. Science. 2016; 352(6282): 169–175.
    CrossRefPubMed
  7. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer. 2004; 4(6): 448–456.
    CrossRefPubMed
  8. Książkiewicz M, Markiewicz A, Zaczek AJ. Epithelial-mesenchymal transition: a hallmark in metastasis formation linking circulating tumor cells and cancer stem cells. Pathobiology. 2012; 79(4): 195–208.
    CrossRefPubMed
  9. Guarino M. Epithelial-mesenchymal transition and tumour invasion. Int J Biochem Cell Biol. 2007; 39(12): 2153–2160.
    CrossRefPubMed
  10. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009; 119(6): 1429–1437.
    CrossRefPubMed
  11. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest. 2009; 119(6): 1417–1419.
    CrossRefPubMed
  12. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002; 2(6): 442–454.
    CrossRefPubMed
  13. Babayan A, Hannemann J, Spötter J, et al. Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. PLoS One. 2013; 8(9): e75038.
    CrossRefPubMed
  14. Paoletti C, Larios JM, Muñiz MC, et al. Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance. Mol Oncol. 2016; 10(7): 1078–1085.
    CrossRefPubMed
  15. Miyamoto DT, Zheng Yu, Wittner BS, et al. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science. 2015; 349(6254): 1351–1356.
    CrossRefPubMed
  16. Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014; 371(11): 1028–1038.
    CrossRefPubMed
  17. Menen RS, Pinney E, Kolostova K, et al. A rapid imageable in vivo metastasis assay for circulating tumor cells. Anticancer Res. 2011; 31(10): 3125–3128.
    PubMed
  18. Spizzo G, Went P, Dirnhofer S, et al. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat. 2004; 86(3): 207–213.
    CrossRefPubMed
  19. Spizzo G, Fong D, Wurm M, et al. EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J Clin Pathol. 2011; 64(5): 415–420.
    CrossRefPubMed
  20. Rao CG, Chianese D, Doyle GV, et al. Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int J Oncol. 2005; 27(1): 49–57.
    PubMed
  21. Bobek V, Cegan M, Kolostova K. Circulating tumour cells in patients with urothelial tumours: Enrichment and in vitro culture. Can Urol Assoc J. 2014; 8(9-10): E715–E720.
    CrossRefPubMed
  22. Menen R, Pinney E, Hassanein MK, et al. Inhibition of metastasis of circulating human prostate cancer cells in the chick embryo by an extracellular matrix produced by foreskin fibroblasts in culture. Anticancer Res. 2012; 32(5): 1573–1577.
    PubMed
  23. Bobek V, Hoffman RM, Kolostova K. Site-specific cytomorphology of disseminated PC-3 prostate cancer cells visualized in vivo with fluorescent proteins. Diagn Cytopathol. 2013; 41(5): 413–417.
    CrossRefPubMed
  24. Kolostova K, Broul M, Schraml J, et al. Circulating tumor cells in localized prostate cancer: isolation, cultivation in vitro and relationship to T-stage and Gleason score. Anticancer Res. 2014; 34(7): 3641–3646.
    PubMed
  25. Kolostova K, Pinterova D, Hoffman RM, et al. Circulating human prostate cancer cells from an orthotopic mouse model rapidly captured by immunomagnetic beads and imaged by GFP expression. Anticancer Res. 2011; 31(5): 1535–1539.
    PubMed
  26. Wagner JA, Williams SA, Webster CJ. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther. 2007; 81(1): 104–107.
    CrossRefPubMed
  27. Humphrey PA, Moch H, Cubilla AL, et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016; 70(1): 106–119.
    CrossRefPubMed
  28. de Bono JS, Kristeleit R, Tolcher A, et al. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin Cancer Res. 2008; 14(20): 6663–6673.
    CrossRefPubMed
  29. Scher HI, Jia X, de Bono JS, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 2009; 10(3): 233–239.
    CrossRefPubMed
  30. Goldkorn A, Ely B, Quinn DI, et al. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol. 2014; 32(11): 1136–1142.
    CrossRefPubMed
  31. Fleisher M, Danila DC, Fizazi K, et al. Circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide post-chemotherapy (phase 3 AFFIRM study). J Clin Oncol. 2015; 33(Suppl): 5035.
  32. Scher HI, Heller G, Molina A, et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol. 2015; 33(12): 1348–1355.
    CrossRefPubMed
  33. Lorente D, Olmos D, Mateo J, et al. Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer. Eur Urol. 2016; 70(6): 985–992.
    CrossRefPubMed
  34. Danila DC, Heller G, Gignac GA, et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res. 2007; 13(23): 7053–7058.
    CrossRefPubMed
  35. Sonpavde G, Pond GR, Berry WR, et al. The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. Cancer. 2011; 117(17): 3963–3971.
    CrossRefPubMed
  36. Quinn DI, Tangen CM, Hussain M, et al. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol. 2013; 14(9): 893–900.
    CrossRefPubMed
  37. de Bono JS, Logothetis CJ, Molina A, et al. COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364(21): 1995–2005.
    CrossRefPubMed
  38. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989; 8(4): 431–440.
    PubMed
  39. Scher HI, Halabi S, Tannock I, et al. Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26(7): 1148–1159.
    CrossRefPubMed
  40. Halabi S, Armstrong AJ, Sartor O, et al. Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. J Clin Oncol. 2013; 31(31): 3944–3950.
    CrossRefPubMed
  41. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007; 25(25): 3965–3970.
    CrossRefPubMed
  42. Petrylak DP, Ankerst DP, Jiang CS, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006; 98(8): 516–521.
    CrossRefPubMed
  43. Morris MJ, Molina A, Small EJ, et al. Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. J Clin Oncol. 2015; 33(12): 1356–1363.
    CrossRefPubMed
  44. Abbosh PH, Rosenberg JE, Plimack ER. Circulating biomarkers to guide systemic therapy for urothelial carcinoma. Urol Oncol. 2016; 34(11): 502–509.
    CrossRefPubMed
  45. Cegan M, Kolostova K, Matkowski R, et al. In vitro culturing of viable circulating tumor cells of urinary bladder cancer. Int J Clin Exp Pathol. 2014; 7(10): 7164–7171.
    PubMed
  46. Cowan NC, Crew JP. Imaging bladder cancer. Curr Opin Urol. 2010; 20(5): 409–413.
    CrossRefPubMed
  47. Gradilone A, Petracca A, Nicolazzo C, et al. Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer. BJU Int. 2010; 106(5): 710–715.
    CrossRefPubMed
  48. Rink M, Chun FKH, Minner S, et al. Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer. BJU Int. 2011; 107(10): 1668–1675.
    CrossRefPubMed
  49. Osman I, Kang M, Lee A, et al. Detection of circulating cancer cells expressing uroplakins and epidermal growth factor receptor in bladder cancer patients. Int J Cancer. 2004; 111(6): 934–939.
    CrossRefPubMed
  50. Güdemann CJ, Weitz J, Kienle P, et al. Detection of hematogenous micrometastasis in patients with transitional cell carcinoma. J Urol. 2000; 164(2): 532–536.
    PubMed
  51. Bluemke K, Bilkenroth U, Meye A, et al. Detection of circulating tumor cells in peripheral blood of patients with renal cell carcinoma correlates with prognosis. Cancer Epidemiol Biomarkers Prev. 2009; 18(8): 2190–2194.
    CrossRefPubMed
  52. Nel I, Gauler TC, Bublitz K, et al. Circulating Tumor Cell Composition in Renal Cell Carcinoma. PLoS One. 2016; 11(4): e0153018.
    CrossRefPubMed
  53. Miyamoto DT, Lee RJ, Stott SL, et al. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov. 2012; 2(11): 995–1003.
    CrossRefPubMed
  54. Markowski MC, Frick KD, Eshleman JR, et al. Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide. Prostate. 2016; 76(16): 1484–1490.
    CrossRefPubMed
  55. Bernemann C, Schnoeller TJ, Luedeke M, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur Urol. 2017; 71(1): 1–3.
    CrossRefPubMed
  56. Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161(5): 1215–1228.
    CrossRefPubMed
  57. Barbieri CE, Bangma CH, Bjartell A, et al. The mutational landscape of prostate cancer. Eur Urol. 2013; 64(4): 567–576.
    CrossRefPubMed
  58. Attard G, de Bono JS, Logothetis CJ, et al. Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. Clin Cancer Res. 2015; 21(7): 1621–1627.
    CrossRefPubMed
  59. Reyes EE, VanderWeele DJ, Isikbay M, et al. Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer. J Transl Med. 2014; 12: 313.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2024 Via Medica Regulations Cookie policy Privacy Statement Legal Note